All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, February 27, 2021
Home » Blogs » BioWorld MedTech Perspectives » Israel is the land of milk, honey and med-tech

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / Cardiovascular / Diagnostics / Imaging / Biomaterials

Israel is the land of milk, honey and med-tech

June 3, 2011
By Holland Johnson
No Comments

When one thinks about countries that are hotbeds for medical technology innovation, Israel would not likely be at the top of anyone’s list. But people in the know will tell you that this small country, with a population of just a shade over 7.5 million people, has a reputation for being a tireless innovator in the field, with countries from all over the world flocking there to study their business model.

According to the Israeli Life Science Industry, an advocacy group, the med-tech industry is also young and growing. Of the currently operating 702 companies, 56% were founded during the last decade. A closer look reveals that a quarter (173 companies) of the industry was established in the last five years.  According to Israel Lifescience Industry, 56% (396) of the 702 companies were created within the last decade. Of those, 27% or 105 companies are revenue generating entities. The remaining 214 revenue generating companies are mature and were created prior to 2001. More impressive is the fact that 25 companies or 8% of all revenue producing companies were established within the last five years. Approximately 16% of the life science industry or 110 companies are at the seed stage, 11% or 74 companies are at the preclinical stage and 146 or 21% of the companies are at the clinical stage. The Israeli Life Science Industry is heavily biased towards the medical device sector, with 401 companies or 57% of the total. The largest sub sector in the medical device arena is the one containing therapeutic devices, both implantable and disposable. The latter comprises 41% of the total medical device body of companies, followed by medical equipment, diagnostic, imaging and monitoring companies contributing 18%, 13%, 11% and 6%, respectively.

“Israel is a treasure trove for the biomedical world community” Ruth Alon, Chair of the recent ILSI Biomed 2011 conference told Medical Device Daily.

At the Biomed meeting, Cedric Bisson MD, Managing Partner at iNovia Healthcare Ventures (Montreal, Quebec), told MDD Israel Editor Jonathan Goldstein that the Israeli technology community had nurtured itself on the need to export to survive, the lack of natural resources, and a strong and innovative entrepreneurial culture. In addition, government incentives and support, he felt, were key ingredients in the recipe. Examples included incubator programs, small company loans, binational collaborative grants, and other customized and well adapted programs. To go to the next level, he mentioned Israel’s need for an ecosystem containing adequately financed funds with a critical mass of local senior partners; he confirmed that Israel’s recent investment in Orbimed (New York)  appeared to be a significant step in this direction.

Goldstein also noted that the standard Israeli company is often not blessed with corporate or investment partners who have an innate understanding of the clinical and market environments. But it often has at its helm experienced managers, high-quality advisers (often from top U.S. centers) and energy and passion that takes the company far beyond what might be seen as normal elsewhere.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Seniors with wooden puzzle

    Cassava’s simufilam improves AD patients’ cognition, behavior

    BioWorld
    When Cassava Sciences Inc.’s president and CEO, Remi Barbier, opened up the interim analysis of the company’s open-label study for Alzheimer’s disease candidate...
  • Vaxart COVID-19 vaccine tablets

    Vaxart shares shaken despite apparently positive early data for oral COVID-19 vaccine

    BioWorld
    Vaxart Inc. investors who stuck by company shares Feb. 3 had to swallow a bitter pill – watching shares of the oral vaccine developer (NASDAQ:VXRT) fall 57.8% to...
  • IPO money

    Lucira Health launches $153M IPO

    BioWorld MedTech
    Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 26.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing